vorasidenib,nivolumab
servier,bms
['nivo', 'vorasidenib', 'indigo']
so asco plenary ranking from my side ( from trial quality and practical use , assuming no cost constraints) no 1 - vorasidenib - indigo ( i will use it - hopefully no long term resistance issue . ) no 2 - nivo -avd ( i will think about it and discuss with patient ) 
Oncology care , to give or not to give chemo , data analysis , oncology pharamocovigilance , enthusiastic critic, twitts are not twists